Ultra-LEAF™ Purified anti-human SCF (KITLG) Antibody, SCF, W24015B,BioLegend,648721

Host

Rat

Reactivity

Human

Application

Neut - Quality tested

Platform ID

BAB025243493

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NameUltra-LEAF™ Purified anti-human SCF (KITLG) Antibody, SCF, W24015B
Cat. No.648721
HostRat
IsotypeRat IgG1, κ
ReactivityHuman
ApplicationNeut - Quality tested
ClonalityMonoclonal
Clone NumberW24015B
ConcentrationThe antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in ourCertificate of Analysisonline tool.
TargetSCF
ImmunogenRecombinant human SCF
PurityThe Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Formulation0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
StorageThe antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Regulatory StatusResearch Use Only

Scientific Background

Stem Cell Factor (SCF) was initially synthesized as a membrane-bound protein with 248 or 220 amino acids, depending on alternative splicing of exon 6. The 248 amino acid form contains a proteolytic cleavage site encoded by exon 6. It is cleaved from the cell to release an active soluble protein of 165 amino acid residues. Soluble SCF is glycosylated at both N-linked and O-linked sites. MMP-9 plays a physiological role in SCF release from the membrane. This action plays a significant role in differentiating and mobilizing stem and progenitor cells from the bone marrow. SCF increases the proliferation of myeloid and lymphoid hematopoietic progenitors in bone marrow cultures. SCF/c-kit interaction in mast cells results in mast cell degranulation with release of mediators, such as histamine and inflammatory cytokines and chemokines. Also, activation of c-kit in dendritic cells regulates T helper cell differentiation and allergic asthma. In addition, SCF plays an important role in revascularization of ischemic limbs. Ischemia induces plasma elevation of SCF and thrombopoietin (TPO). At lower levels, GM-CSF and erythropoietin (EPO). SCF and TPO induce the release of CXCL12 from platelets, thereby increasing CXCL12 levels in plasma. This results in an extensive mobilization of CXCR4+VEGFR1+ cells (hemangiocytes), accelerating revascularization of the ischemic limbs. SCF binds to its receptor kit that belongs to the type III tyrosine kinase family, whose members include receptors for M-CSF and PDGF.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.